OVERSEA CHINESE BANKING Corp Ltd Invests $1.37 Million in IQVIA Holdings Inc. $IQV

OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,080 shares of the medical research company’s stock, valued at approximately $1,368,000.

Several other institutional investors have also bought and sold shares of IQV. BlackRock Inc. acquired a new position in IQVIA during the second quarter worth $2,811,292,000. Boston Partners acquired a new stake in shares of IQVIA in the 3rd quarter valued at $676,698,000. Norges Bank acquired a new stake in shares of IQVIA in the 4th quarter valued at $497,445,000. Victory Capital Management Inc. grew its holdings in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its position in shares of IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after purchasing an additional 933,554 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last ninety days. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on IQV. Mizuho lifted their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. TD Cowen upped their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. HSBC reissued a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Stock Performance

IQV stock opened at $260.17 on Friday. The company has a 50 day moving average price of $213.32 and a 200 day moving average price of $187.52. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $260.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.82 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.